NEFM and frontotemporal dementia: In this study we developed a quantitative and highly sensitive immunoassay to measure NfM levels in CSF and subsequently utilise it for the analysis of NfM in the CSF of patients with neurological disorders, including ALS, AD, FTD, and LBD, alongside control cohorts.